Extracellular vesicles containing ACE2 efficiently prevent infection by SARS‐CoV‐2 Spike protein‐containing virus

Abstract

SARS‐CoV‐2 entry is mediated by binding of the spike protein (S) to the surface receptor ACE2 and subsequent priming by host TMPRSS2 allowing membrane fusion. Here, we produced extracellular vesicles (EVs) exposing ACE2 and demonstrate that ACE2‐EVs are efficient decoys for SARS‐CoV‐2 S protein‐containing lentivirus. Reduction of infectivity positively correlates with the level of ACE2, is much more efficient than with soluble ACE2 and further enhanced by the inclusion of TMPRSS2.

Cited by papers we hold 6

• Quantitative characterisation of extracellular vesicles designed to decoy or compete with SARS-CoV-2 reveals differential mode of action across variants of concern and highlights the diversity of Omicron · 2025
  Not checked
• Overview and Update on Extracellular Vesicles: Considerations on Exosomes and Their Application in Modern Medicine · 2022
  No notice
• Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2 · 2022
  No notice
• In Vitro Neuroprotective Effects of Macrophage Membrane-Derived Curcumin-Loaded Carriers against 1‑Methyl-4-phenylpyridinium-Induced Neuronal Damage · 2021
  Not checked
• Development of Extracellular Vesicle Therapeutics: Challenges, Considerations, and Opportunities · 2021
  No notice
• Circulating Exosomes Are Strongly Involved in SARS-CoV-2 Infection · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.